Physician profile
Michael J Ostempowski
NPI 1447262209
$3,653.00
in general payments reported to CMS, 2019-2025
11 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $37.50 · 2021: $464 · 2022: $373 · 2023: $1,011 · 2024: $336 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Travel and Lodging: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.26 |
| Travel and Lodging | $563.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $2,375.14 | 2019-2025 | Velys, Actis |
| Abbott Laboratories | $324.25 | 2021-2022 | |
| Medical Device Business Services, INC. | $278.79 | 2019-2023 | Attune |
| Impulse Dynamics (USA) INC. | $262.81 | 2024-2025 | Optimizer |
| Zimmer Biomet Holdings, INC. | $147.14 | 2025 | G7 |
| Pacira Therapeutics, INC. | $133.24 | 2019-2021 | |
| Stryker Corporation | $43.30 | 2024 | Insignia, Mako |
| Smith+Nephew, INC. | $37.50 | 2020 | |
| Bioventus LLC | $20.85 | 2024 | Durolane |
| Pacira Pharmaceuticals Incorporated | $15.88 | 2023 | Iovera, Zilretta, Exparel |
| Merck Sharp & Dohme LLC | $14.10 | 2025 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ostempowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.